Pegylated liposomal doxorubicin: a guide to its use in various malignancies.

Abstract

Pegylated liposomal doxorubicin (Caelyx(®) [EU], Doxil(®) [USA]) represents an improved formulation of conventional doxorubicin, with reduced cardiotoxicity and an improved pharmacokinetic profile. As shown by evidence from clinical trials, intravenous pegylated liposomal doxorubicin is a useful option in the treatment of various malignancies, including metastatic breast cancer, ovarian cancer, multiple myeloma, and AIDS-related Kaposi sarcoma. It has a favourable safety profile relative to conventional doxorubicin and other available chemotherapy agents.

• Authors: Katherine A Lyseng-Williamson, Sean T Duggan, Gillian M Keating
• Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (BioDrugs) Vol. 27 Issue 5 Pg. 533-40 (Oct 2013) ISSN: 1179-190X [Electronic] New Zealand
• PMID: 24018470 (Publication Type: Journal Article, Review)

Chemical References

• Antibiotics, Antineoplastic
• liposomal doxorubicin
• Polyethylene Glycols
• Doxorubicin

Topics

• Antibiotics, Antineoplastic (adverse effects, therapeutic use)
• Clinical Trials, Phase II as Topic
• Clinical Trials, Phase III as Topic
• Doxorubicin (adverse effects, analogs & derivatives, therapeutic use)
• Humans
• Neoplasms (drug therapy)
• Polyethylene Glycols (adverse effects, therapeutic use)
• Randomized Controlled Trials as Topic